Accordingly, we found that combining cisplatin and Hsp70 inhibitors (VER-155008, or JG-98) with early-stage (SAR405) or late-stage (CQ) autophagic inhibitors resulted in a robust reduction in the metabolic, clonogenic, and proliferative activities of tumor cells, as well as in cell viability in 2D and 3D spheroid models, which suggests an induction of pro-survival autophagy following Hsp70 inhibition. Here, HSPA1A is linked to neoplasm.